CASE 3 48 yo man HIV positive/HEP C positive 12 yrs ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs CD4 310/40% HIV Viral Load <40.

Slides:

Advertisements

Similar presentations

Optimal therapy in genotype 2 and 3 patients Antonio Craxì Liver & GI Unit, Di.Bi.M.I.S., University of Palermo, Italy

Advertisements

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.

TWH LIVER CENTRE UHN centre of excellence A case study: Hepatitis C treatment and severe anemia Colina Yim RN(EC), MN Nurse Practitioner CAHN 2013.

CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):

Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.

A5336 A Phase IIa, Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults CAB Draft Discussion.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

CASE 2 48 yo man IVDU in past….last used 27 yrs ago Stable social situation Currently receiving social assistance with provincial drug coverage No comorbid.

J OURNAL C LUB : T HE R ANDOMIZED C ONTROLLED T RIAL July 10 th, 2008 Rakhi Naik, MD.

Hepatitis web study Hepatitis web study Sofosbuvir in Genotypes 2 or 3 VALENCE Trial Phase 3 Treatment Naïve and Treatment Experienced Zeuzem S, et al.

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection NIAID ERADICATE Trial Phase 2a Treatment Naïve and Treatment.

 During his annual physical in Dec 2007, Mr. A, a 42 y old pilot, presented with elevated liver enzymes and positive antibodies to HCV.  He had no symptoms.

Hepatitis C Disease & Treatment.

Module 6: Treatment options. Module goal To enable participants understand the best current treatment options, factors that influence outcomes and potential.

CASE 2 49 yo man HIV positive 16 yrs. ago CD4 15 on diagnosis Disseminated cutaneous Kaposi’s Sarcoma.

CASE 4 67 yo man HIV Hypertensive CD4 on diagnosis 110/7% AZT initiated soon after diagnosis.

CASE 1 55 yo man…Baker HIV+ since 1996 Refused bloodwork over the years as was ‘Feeling fine’ Oral hairy leukoplakia noted on oral biopsy in 2001.

VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.

Renal Transplantation for HIV/HCV Co-infected Patients Solid Organ Transplantation and People With HIV: Ethics and Policy Conference David Oldach & Robert.

Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

VIRTUAL MEDZONE Your Resource for Hepatitis Related Innovative Medical Communication.

CASE 3 63 yo man HIV positive G1a chronic Hepatitis C… Recent HIV history TDF/FTC/RTV/Atazanavir with CD4 480 and HIV viral load

CASE 2 49 yo man HIV Bipolar 2 disorder highlighted by major depression with a few serious suicide attempts and necessitating multiple hospital admissions.

NYU Medical Grand Rounds Clinical Vignette Alexander Jow, PGY-3 February 21, 2012 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

Hepatitis C: The Next Tsunami Danny Jenkins Cri-Help Common Ground – The Westside HIV Community Center We Write the Grants

Two Men with Extensive Genital Ulcer Disease Recent Cases at the Denver Metro Health Clinic.

1. Sustained suppression of HBV replication Decrease in serum HBV DNA to

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

Alessio Aghemo First Division of Gastroenterology Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico Università degli Studi di Milano 5 th Paris.

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

Hepatitis web study Hepatitis web study Sofosbuvir ELECTRON (Overview): 6 parts, 22 arms Phase 2 Treatment Naïve and Treatment Experienced Source: Gilead.

CASE 5 54 yo man HIV positive in 2001 Immune Thrombocytopenia Chronic G1a Hepatitis C Crack use daily Normotensive.

CASE 3 43 yo man HIV+ since 2005 CD4 nadir 190 Baseline genotype…clear.

IAS–USA Special Considerations: When and What to Start with Viral Hepatitis Coinfections Joseph J. Eron, Jr, MD Professor of Medicine University of North.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

Hepatitis B The Basics David Wong University of Toronto March 2005.

CASE 3 62 yo man Genotype 1b chronic hepatitis C Cirrhosis No previous ascites/encephalopathy OGD revealed a few very small esophageal varices.

W24 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve Early fibrosis to compensated cirrhosis No HBV or HIV co-infection N = 10 SOF + weight-based.

Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir in GT1 with Cirrhosis OPTIMIST-2 Trial Phase 3 Treatment Naïve and Treatment Experienced.

Case study 35 Year old male. Background HIV Positive – Stavudine/Lamivudine/Lopinavir Ritonavir combination Renal Failure for 2 years Receive a transplant.

Clinical Case HCV therapy following liver transplantation.

CASE 2 58 yo man IVDU in past….last used 35 yrs ago Genotype 1a Chronic Hepatitis C Type II Diabetes Private drug plan coverage.

CASE 3 48 yo man HIV positive/HEP C positive 12 yrs. ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs. CD4 310/40% HIV Viral Load

Clinician Consultation Center Indian Health Services California Consortium for Urban Indian Health Hepatitis C Warmline Joanna Eveland, MD Brenda Goldhammer,

CASE 2 54 yo man…HIV PCP Cryptospordiasis Chronic HepC Genotype 1a Biopsy… 2/4 activity, 3/4scarring CD4 40 No baseline genotype.

CASE 1 54 yo man HIV Generalized Anxiety/OCD VL 15,185 CD4 ranges from Baseline Genotype clear.

CASE 1 54 yo man HIV positive 8 yrs ago Tenofovir/FTC/RTV/Atazanavir x 4 yrs Previously documented NNRTI resistance with Y181C, G190A,and mixed m184v/wt.

‘Easy to treat’? Graham R Foster Professor of Hepatology Queen Marys University of London.

Hepatitis C Infection By: S/N Maryam Omar. Introduction  Thalassemia patient require life long blood transfusion to sustain their growth and development.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

CASE 4 44 yo man HIV positive 2010 CD4 400 on diagnosis Initiated Abacavir/3TC/Dolutegravir in /2013 CD4 600 HIV viral load

LDV/SOF Randomisation * 1:1 Open-label ≥ 20 years, Japanese Chronic HCV infection Genotype 1 HCV RNA ≥ IU/ml Treatment-naive, or pre-treated Compensated.

Phase 3 Treatment-Naïve and Treatment-Experienced

Sofosbuvir plus Peg-Interferon and Ribavirin in Treatment Experienced Patients with Hepatitis C Virus and HIV Co-Infection Mehri Nikbin, MD Infectious.

CASE 2 53 yo man HIV CD4 340/16% (Nadir) VL 30,100 c/ml.

Complicated cases David Fletcher, MD Department of Medicine University of Toronto.

Phase 2 Treatment Naïve HIV Coinfection

Chronic hepatitis B virus and liver fibrosis: A mathematical model

Chronic Hepatitis C Therapy: Changing the Rules of Duration

History 56 y/o male from Cuba newly diagnosed with hepatitis C genotype 2b in Jan 2008 No symptoms of decompensation.

Simeprevir in HIV Coinfection, GT-1 C212 Trial

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

ASPIRE Study: SMV + PEG-IFN + RBV for genotype 1 experienced patients

Chronic Hepatitis C Therapy: Changing the Rules of Duration

Phase 2 Treatment Experienced (with Sofosbuvir and Ribavirin)

Phase 3 Treatment-Naïve and Treatment-Experienced

Pei-Yuan Su，Yu-Chun Hsu，Shun-Sheng Wu，Wei-Wen Su，Maw-Soan Soon

Presentation transcript:

CASE 3 48 yo man HIV positive/HEP C positive 12 yrs ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs CD4 310/40% HIV Viral Load <40

CASE 3 Genotype 1a Hepatitis C Liver biopsy in 2009 reveals 4/4 scarring with ongoing active inflammation Compensated Cirrhosis and clinically stable OGD negative for varices and U/S negative for hepatoma/Ascites

CASE HIV meds switched form TDF/FTC/RTV/LPV to TDF/FTC/RGV Therapy for Hepatitis C initiated with PEG INF 180mcg/RBV 1200 mg/Boceprevir 2400 mg

CASE 3 Week 0 HCVRNA 1.67 x 10e7 Week 4 HCVRNA 4.22 x 10 e4 Week 8 HCVRNA 1.90 x 10 e1 Week 10 HCVRNA Not detected

CASE 3 WeekWBCPmns

CASE 3 Pegasys dose decreased to 135 mcg Ended up with a fever and was hospitalized with febrile neutropenia…hypotensive…no source of infection found G-csf initiated and titrated up to daily dosing

CASE 3 WeekWBCPmns

CASE 3 Pegasys dose decreased to 90 mcg Ended up with a fever and was hospitalized once again with febrile neutropenia…

CASE 3 Therapy abandoned Over the ensuing 3 years…Pmns remained below 0.5 despite G-csf daily…antibodies to GCSF not detected Bone marrow done and PMN progenitors seen…spleen not huge on U/S Trial of IVIG given without benefit in regards to increasing PMNs

CASE 3 Early 2014 Baseline pmns are Would you retreat with Sofosbuvir/PEGINF/RBV?

CASE 3 Early 2014 Fighting with private insurance to get Sofosbuvir/Simeprevir Denied

CASE 3 Late 2014 Pmns What should we do?

CASE 3 Late 2014 Sofosbuvir/RBV now vs wait for Sofosbuvir/Ledipasvir ABBVIE quad Other?